Compugen sees positives for in-silico targets
TEL AVIV—Compugen has shared positive initial experimental results for two in-silico predicted targets for antibody-drug conjugate (ADC) cancer therapy disclosed in 2013. Both candidates displayed low expression levels in normal critical tissues and higher expression in multiple cancer types, suggesting that both may have potential for ADC therapy in cancer. The candidates are two of five reported on in 2013, and initial validation of the other three is ongoing, as is further testing of these two candidates.
Dr. Anat Cohen-Dayag, Compugen’s president and CEO, noted that “most of our R&D and commercialization efforts are now being directed towards immuno-oncology-related activities supporting our immune checkpoint-based candidates for immunotherapy. As these very promising candidates based on our first discovery program move ahead, we look forward to further broadening the scope and diversity of our Pipeline Program with therapeutic antibodies against ADC targets resulting from our second discovery program.”